Research advances in the molecular classification of gastric cancer.

IF 6.6 2区医学 Q1 Medicine

Cellular Oncology Pub Date : 2024-10-01 Epub Date: 2024-05-08 DOI:10.1007/s13402-024-00951-9

Dike Shi, Zihan Yang, Yanna Cai, Hongbo Li, Lele Lin, Dan Wu, Shengyu Zhang, Qingqu Guo

引用次数: 0

Abstract

Gastric cancer (GC) is a malignant tumor with one of the lowest five-year survival rates. Traditional first-line treatment regimens, such as platinum drugs, have limited therapeutic efficacy in treating advanced GC and significant side effects, greatly reducing patient quality of life. In contrast, trastuzumab and other immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have demonstrated consistent and reliable efficacy in treating GC. Here, we discuss the intrinsic characteristics of GC from a molecular perspective and provide a comprehensive review of classification and treatment advances in the disease. Finally, we suggest several strategies based on the intrinsic molecular characteristics of GC to aid in overcoming clinical challenges in the development of precision medicine and improve patient prognosis.

Abstract Image

查看原文本刊更多论文

胃癌分子分类研究进展。

胃癌（GC）是五年生存率最低的恶性肿瘤之一。传统的一线治疗方案，如铂类药物，对晚期胃癌的疗效有限，且副作用大，大大降低了患者的生活质量。相比之下，曲妥珠单抗和其他免疫检查点抑制剂（如 nivolumab 和 pembrolizumab）在治疗 GC 方面已显示出稳定可靠的疗效。在此，我们从分子角度探讨了 GC 的内在特征，并全面回顾了该疾病的分类和治疗进展。最后，我们根据 GC 的内在分子特征提出了几种策略，以帮助克服精准医疗发展过程中的临床挑战，改善患者预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

10.40

自引率

1.50%

发文量

审稿时长

16 weeks

期刊介绍： The Official Journal of the International Society for Cellular Oncology Focuses on translational research Addresses the conversion of cell biology to clinical applications Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.